491 related articles for article (PubMed ID: 15276015)
1. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease.
Oudit GY; Sun H; Kerfant BG; Crackower MA; Penninger JM; Backx PH
J Mol Cell Cardiol; 2004 Aug; 37(2):449-71. PubMed ID: 15276015
[TBL] [Abstract][Full Text] [Related]
2. Cardiac regulation by phosphoinositide 3-kinases and PTEN.
Oudit GY; Penninger JM
Cardiovasc Res; 2009 May; 82(2):250-60. PubMed ID: 19147653
[TBL] [Abstract][Full Text] [Related]
3. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
4. The biology and clinical relevance of the PTEN tumor suppressor pathway.
Sansal I; Sellers WR
J Clin Oncol; 2004 Jul; 22(14):2954-63. PubMed ID: 15254063
[TBL] [Abstract][Full Text] [Related]
5. Targeting phosphoinositide 3-kinase: moving towards therapy.
Marone R; Cmiljanovic V; Giese B; Wymann MP
Biochim Biophys Acta; 2008 Jan; 1784(1):159-85. PubMed ID: 17997386
[TBL] [Abstract][Full Text] [Related]
6. Signalling through Class I PI3Ks in mammalian cells.
Hawkins PT; Anderson KE; Davidson K; Stephens LR
Biochem Soc Trans; 2006 Nov; 34(Pt 5):647-62. PubMed ID: 17052169
[TBL] [Abstract][Full Text] [Related]
7. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells.
Van de Sande T; De Schrijver E; Heyns W; Verhoeven G; Swinnen JV
Cancer Res; 2002 Feb; 62(3):642-6. PubMed ID: 11830512
[TBL] [Abstract][Full Text] [Related]
8. PTEN and myotubularin: novel phosphoinositide phosphatases.
Maehama T; Taylor GS; Dixon JE
Annu Rev Biochem; 2001; 70():247-79. PubMed ID: 11395408
[TBL] [Abstract][Full Text] [Related]
9. Pten signaling in gliomas.
Knobbe CB; Merlo A; Reifenberger G
Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
[TBL] [Abstract][Full Text] [Related]
10. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
11. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells.
Kandasamy K; Srivastava RK
Cancer Res; 2002 Sep; 62(17):4929-37. PubMed ID: 12208743
[TBL] [Abstract][Full Text] [Related]
12. PTEN: life as a tumor suppressor.
Simpson L; Parsons R
Exp Cell Res; 2001 Mar; 264(1):29-41. PubMed ID: 11237521
[TBL] [Abstract][Full Text] [Related]
13. Phosphoinositide 3-kinase gamma: kinase-dependent and -independent activities in cardiovascular function and disease.
Alloatti G; Montrucchio G; Lembo G; Hirsch E
Biochem Soc Trans; 2004 Apr; 32(Pt 2):383-6. PubMed ID: 15046613
[TBL] [Abstract][Full Text] [Related]
14. Regulation of phosphoinositide metabolism, Akt phosphorylation, and glucose transport by PTEN (phosphatase and tensin homolog deleted on chromosome 10) in 3T3-L1 adipocytes.
Ono H; Katagiri H; Funaki M; Anai M; Inukai K; Fukushima Y; Sakoda H; Ogihara T; Onishi Y; Fujishiro M; Kikuchi M; Oka Y; Asano T
Mol Endocrinol; 2001 Aug; 15(8):1411-22. PubMed ID: 11463863
[TBL] [Abstract][Full Text] [Related]
15. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention.
Steelman LS; Bertrand FE; McCubrey JA
Expert Opin Ther Targets; 2004 Dec; 8(6):537-50. PubMed ID: 15584861
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
[TBL] [Abstract][Full Text] [Related]
17. Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN.
Downes CP; Bennett D; McConnachie G; Leslie NR; Pass I; MacPhee C; Patel L; Gray A
Biochem Soc Trans; 2001 Nov; 29(Pt 6):846-51. PubMed ID: 11709086
[TBL] [Abstract][Full Text] [Related]
18. PTEN permits acute increases in D3-phosphoinositide levels following TCR stimulation but inhibits distal signaling events by reducing the basal activity of Akt.
Seminario MC; Precht P; Bunnell SC; Warren SE; Morris CM; Taub D; Wange RL
Eur J Immunol; 2004 Nov; 34(11):3165-75. PubMed ID: 15468057
[TBL] [Abstract][Full Text] [Related]
19. [Involvement of phosphoinositide 3-kinases and phosphoinositide phosphatases in immune responses, glucose metabolism and tumorigenesis].
Sasaki T; Sasaki J; Suzuki A; Penninger JM
Tanpakushitsu Kakusan Koso; 2001 Sep; 46(12):1820-9. PubMed ID: 11552264
[No Abstract] [Full Text] [Related]
20. Insulin-like growth factor-1 and PTEN deletion enhance cardiac L-type Ca2+ currents via increased PI3Kalpha/PKB signaling.
Sun H; Kerfant BG; Zhao D; Trivieri MG; Oudit GY; Penninger JM; Backx PH
Circ Res; 2006 Jun; 98(11):1390-7. PubMed ID: 16627784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]